Filing summary
Entity note: The supplied filing is Immudyne, Inc.’s Form 10-Q, not a filing identified as LifeMD, Inc. Investors should confirm the issuer before relying on this summary. The reporting period is the three months ended March 31, 2014; the financial statements are unaudited.
Business context
Immudyne develops, manufactures, and sells yeast beta-glucan nutraceutical and cosmetic products. It reported focusing sales and marketing on oral and topical products, healthcare professionals, distributors, and direct-to-consumer sales, after completing its exit from feed-additive products in 2013.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 or prior balance-sheet date |
|---|---|---|
| Sales | $192,429 | $230,258 |
| Gross profit / gross margin | $143,339 / 74.5% | $177,358 / 77.0% |
| Operating expenses | $320,977 | $248,145 |
| Operating loss | $177,638 | $70,787 |
| Net loss | $140,939 | $41,487 |
| Cash from operating activities | $(6,647) | $(60,013) |
| Cash at period end | $36,409 | $38,917 at March 31, 2013 |
| Current assets / current liabilities | $241,055 / $218,886 | $450,726 / $325,562 at December 31, 2013 |
| Total liabilities | $244,986 | $355,962 at December 31, 2013 |
Sales declined 16.4% year over year. Management attributed the decline to a major customer postponing customary first-quarter orders until the second quarter after ending 2013 with product inventory. Gross profit fell 19.2%, and gross margin contracted 2.5 percentage points. Operating expenses rose 29.4%, primarily due to marketing and compensation costs, along with higher professional fees. The filing reports basic and diluted loss per share of $(0.00).
Operating cash outflow improved from the prior-year quarter, chiefly because the company collected $132,000 of legal settlement proceeds. Cash nevertheless fell $118,647 during Q1, including a $100,000 investment in Adiuvo Investment S.A. and $12,000 of note repayment. Net working capital was $22,169 at March 31, 2014; the company reported a current ratio of 1.1 to 1. Notes payable to officers and directors were $28,200, due on demand at 5% interest.
Outlook, risks, and unusual items
- Going concern and funding: The company disclosed substantial doubt about its ability to continue as a going concern. Management estimated it would need additional capital for 2014 operating and capital requirements, to be sought through higher sales, equity issuance, or debt financing; availability and terms were not assured.
- Customer concentration: One customer represented 92% of Q1 sales and 99% of accounts receivable at March 31, 2014, creating significant concentration risk.
- Costs and execution: Management expected marketing and selling, general, and administrative costs to increase as it pursued growth. It cited intellectual-property protection, regulation, and inadequate capital as factors that could affect results.
- Related royalty obligation: Royalties equal to 8% of certain skincare sales remained subject to an approximately $51,000 commitment. Accrued amounts included $102,000; the president has a 60% interest in the royalty payments and had deferred payment without interest.
- Other items: Q1 included a $25,000 patent-license installment and $7,877 of other income from writing off an old payable. The company issued 100,000 shares to a consultant for services valued at $28,000. Its $100,000 Adiuvo investment was carried at no value on the balance sheet.
- Controls and legal matters: Management concluded disclosure controls were ineffective and identified material weaknesses involving segregation of duties, written accounting and reporting procedures, IT access and disaster recovery, and a whistleblower policy. Management reported no known legal proceedings expected to have a material adverse effect.
The filing gives no quantified sales or earnings guidance. Its forward-looking statements are subject to risks and the company disclaimed an obligation to update them except as required by law.
Important facts to verify
- Confirm that Immudyne, Inc.—rather than LifeMD, Inc.—is the intended issuer and filing.
- Assess near-term liquidity and the feasibility, timing, and dilution or debt terms of planned financing.
- Check whether the delayed major-customer orders were placed and whether customer concentration has changed.
- Verify the status and accounting of the Adiuvo investment and associated options.
- Reconcile the legal settlement amounts and collection disclosures across the filing’s notes and management discussion.
- Track remediation of the disclosed material weaknesses and payment of accrued royalties.